MedTrace Logo

One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study

NCT03662919 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2274

Last updated 2022-10-18

No results posted yet for this study

Summary

A study to describe the one-year persistence in participants treated by Flixabi (infliximab) or Imraldi (Adalimumab) as prescribed by the physician for each of the 5 following indications: Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA), Crohn's Disease (CD) \[adults and children\] and Ulcerative Colitis (UC) \[adults for both treatments and children only for Flixabi\].

Conditions

  • Arthritis, Rheumatoid
  • Spondylitis, Ankylosing
  • Arthritis, Psoriatic
  • Crohn's Disease
  • Colitis, Ulcerative

Interventions

DRUG

Infliximab

Administered as specified in the treatment arm.

DRUG

Adalimumab

Administered as specified in the treatment arm.

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Biogen

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-02
Primary Completion
2022-06-30
Completion
2022-06-30
FDA Drug
Yes

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03662919 on ClinicalTrials.gov